Interim Board of DirectorsThe ASCC is currently governed by an Interim Board of Directors made up of representatives from three of the Centre’s Members and an independent Chair. The Members of the Interim Board are
Emeritus Professor Graham Macdonald Independent executive Chairman appointed to the Board 26 September 2008. Professor Macdonald brings a wealth of experience in clinical medicine, basic biomedical science and in the field of licensing and commercialisation to the Australian Stem Cell Centre. He has had an outstanding career first as an academic nephrologist and then moving into the pharmaceutical industry and holding the positions of Medical Director and External Licensing Coordinator at Merk Sharp and Dohme (Australia) during which he successfully brokered a number of high profile agreements including a US$100 million-plus deal with AMRAD (now Zenyth Therapeutics) to develop a new asthma treatment.
Professor Edwina Cornish Non-executive Director appointed to the Board on 5 September 2008. Professor Cornish is currently Deputy Vice-Chancellor of Research at Monash University. She has also served on the Board of the Australian Research Council, the Prime Minister’s Science and Engineering Council and the Victorian Government Science and Engineering Technology Taskforce. She is a Fellow of the Australian Academy of Technological Sciences and Engineering, and has been awarded the Centenary Medal for service to Australian society in biotechnology and university administration. Professor Cornish played a key role in building one of Australia’s first biotechnology companies, Florigene Ltd.
Professor David Siddle Non-executive Director appointed to the Board on 5 September 2008. Professor Siddle is currently Deputy Vice-Chancellor of Research at the University of Queensland. Professor Siddle is an experimental psychologist with interests in the areas of orienting, attention and conditioning. After completing his PhD, he spent time in both the UK and the US. Professor Siddle is a Director of the Australian Synchrotron Company and Australian Synchrotron Holding Company; AHURI Queensland Research Centre Ltd; CRCMining and IMB Com Pty Ltd. He chaired the National Committee of DVCs/PVCs (Research) in 2001 and was convenor of the Go8 DVCs(R) until December 2007.
Doctor Henry De Aizpurua Non-executive Director appointed to the Board on 5 September 2008. Dr De Aizpurua is currently Head of Business Development at the Howard Florey Institute, and is responsible for the management of all aspects of the Institute’s intellectual property and commercialisation opportunities. He previously worked as a medical researcher at the Mayo Clinic and Foundation (US) and the Walter and Eliza Hall Institute of Medical Research before moving into the life sciences industry, working with Sigma Aldrich for a number of years. Dr De Aizpurua is a Board member of NeuProtect Pty Ltd, Radical Biotechnology Pty Ltd and Nephrodynamics Pty Ltd. |
David Trewern Design